ArticleCancer science2022

A phase 1 trial of xentuzumab, an IGF-neutralizing antibody, in Japanese patients with advanced solid tumors.

Toshihiko Doi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.